Semen Analysis Accuracy and Consequences on Therapeutic Decisions

Male-factor infertility accounts for nearly half of all infertility cases worldwide, yet conventional semen analysis methods—both manual and computer-assisted—can yield inconsistent results. Such inaccuracy can lead to misleading diagnosis, unnecessary interventions (e.g., IVF/ICSI), and potentially increased healthcare costs. Here, we present a novel imaging system, LuceDX, which uses a 13-fold expanded field of view (FOV) to overcome the statistical and technical limitations of standard Computer Assisted Semen Analysis (CASA) tools. By capturing a substantially larger sample area, LuceDX mitigates the non-uniform sperm distribution and clustering effects that compromise accuracy in smaller FOV methods. Pilot data indicate that this expanded-FOV platform improves measurement precision by a factor of 3.6 relative to conventional techniques, aligning with WHO guidelines while reducing the need for multiple fields per sample. This improvement is particularly advantageous in oligospermic men and post-vasectomy assessments, where accurate detection of very low sperm counts is critical in clinical decision making, especially considering real-world settings where guidelines may not be consistently applied. Our discussion highlights the patient and physician benefits of increasing accuracy and reliability toward an even better fertility treatment efficacy and underscores the importance of larger, multi-center trials to validate these findings. Taken together, the evidence suggests that LuceDX’s integrated, AI-enabled advanced image analysis offers a promising step forward in male infertility diagnostics, improving reliability, reducing costs, and potentially accelerating the optimal management of infertile couples.